Concepedia

Cytochrome P 450 2C9 phenotyping using low-dose tolbutamide

Alexander Jetter, Martina Kinzig‐Schippers, Andreas Skott, Andreas Lazar, Dorota Tomalik‐Scharte, Julia Kirchheiner, Monika Walchner‐Bonjean, Ursula Hering, Verena Jakob, Michael Rodamer,

European Journal of Clinical Pharmacology · 2004 · 72 citations · 13 references

DOIFull text

Open access

Concepts

References

13

Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.

Mary V. Relling, Toru Aoyama, Frank J. Gonzalez et al. · Journal of Pharmacology and Experimental Therapeutics · 1990 · 221 citations

, , +16

Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9

Maurice E. Veronese, Peter I. Mackenzie, Christopher J Doecke et al. · Biochemical and Biophysical Research Communications · 1991 · 206 citations

, , +11

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

Julia Kirchheiner, Steffen Bauer, Ingolf Meineke et al. · Pharmacogenetics · 2002 · 169 citations

, , +14

Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment

Amin Rostami‐Hodjegan, S Nurminen, Peter R. Jackson et al. · Pharmacogenetics · 1996 · 126 citations

, , +16

Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers

Maurice E. Veronese, John O. Miners, David Randles et al. · Clinical Pharmacology & Therapeutics · 1990 · 107 citations

, , +13